Article Highlight | 19-Nov-2026

Light-powered relay turns CO₂-derived formate into chiral building blocks for drugs

Westlake University chemists chain visible-light anti-Markovnikov hydrocarboxylation with lipase kinetic resolution, converting alkenyl acetates into chiral β-hydroxy acids at gram scale — including a key intermediate for the cholesterol drug Ezetimibe

Innovation Press

Many blockbuster drugs begin with chiral β-hydroxy acids — small building blocks whose left- or right-handedness decides how the final molecule behaves in the body. Chemists at Westlake University now report in The Innovation Life a way to build them from one of the cheapest carbon sources available: formate, the salt obtained when carbon dioxide is reduced electrochemically.

Formate looks unremarkable, but under visible-light photoredox catalysis it gives up its carbon as CO₂ radical anions — species that are simultaneously powerful one-electron reductants (around −2.2 V versus SCE) and usable C1 units for forging carbon–carbon bonds. The catch is taming that reactivity. The Westlake team's answer is a relay: an excited photosensitizer first abstracts an electron from a thiophenol; the resulting thiyl radical pulls a hydrogen atom off formate to generate CO₂ radical anions; these add to alkenyl acetates in an anti-Markovnikov fashion, and the carbon radicals formed are then reduced and protonated to deliver β-acetoxy acids in good yields across a broad substrate range.

That chemistry hands off to biology. Because the hydrocarboxylation products are racemic, the researchers recruited lipase A from Aspergillus niger to perform kinetic resolution, converting the β-acetoxy acids into chiral β-hydroxy acids with up to 90% enantiomeric excess. Mechanistic studies — including radical trapping experiments — support the radical-mediated pathway the team proposed.

The numbers behind the relay are concrete. The photoredox step runs at 10-millimole, gram scale with no loss of efficiency, turning 1.8 grams of an alkenyl acetate substrate into 2.14 grams of hydrocarboxylation product (89% yield). Lipase resolution then furnished 475 milligrams of the desired (S)-β-acetoxy acid at 48% yield and 90% ee, while the recovered (R)-acetate reached 96% ee and can be recycled. A subsequent reduction delivered a chiral 1,3-diol in 90% yield — the key intermediate for Ezetimibe, the widely prescribed cholesterol-lowering drug.

Notably, the photoredox cycle needs no external reductant or oxidant: hydrogen atoms come from formate itself, and the electrons balance within the catalytic system. The authors present this "neutral" redox profile, together with formate's origin in CO₂ electroreduction, as the sustainability case for the route — a formate economy that converts captured carbon into high-value chiral chemicals rather than fuels alone.

Limitations remain. Enantioselectivities are moderate to good rather than uniform across substrates, kinetic resolution recovers at best half the material as the desired enantiomer, and the radical chemistry has so far been demonstrated on alkenyl acetates rather than broader alkene classes. The team argues, however, that coupling photoredox C–C bond formation with enzymatic resolution is a general design: each step can in principle be swapped for a different light-driven reaction or a different biocatalyst, extending the formate-to-pharma relay to other chiral product families.

###
Xia X., Guo J., Gao Y., et al. (2026). "Harnessing formate as a CO₂ surrogate for chiral β-hydroxy acid synthesis by photoredox hydrocarboxylation of alkenyl acetates." The Innovation Life 4(3), 100224. https://doi.org/10.59717/j.xinn-life.2026.100224

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.